Jailendra Singh
Stock Analyst at Truist Securities
(0.61)
# 3,758
Out of 4,711 analysts
164
Total ratings
17.98%
Success rate
-30.37%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Reiterates: Buy | $295 → $284 | $207.51 | +36.86% | 7 | Dec 18, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $265 → $261 | $197.27 | +32.31% | 13 | Dec 12, 2024 | |
| PHR Phreesia | Maintains: Buy | $31 → $34 | $25.16 | +35.14% | 5 | Dec 11, 2024 | |
| VEEV Veeva Systems | Reiterates: Hold | $207 → $261 | $224.15 | +16.44% | 6 | Dec 6, 2024 | |
| DOCS Doximity | Maintains: Hold | $35 → $49 | $57.83 | -15.27% | 6 | Nov 14, 2024 | |
| PGNY Progyny | Downgrades: Hold | $26 → $19 | $14.34 | +32.50% | 9 | Nov 13, 2024 | |
| PRVA Privia Health Group | Maintains: Buy | $24 → $27 | $20.07 | +34.53% | 6 | Nov 8, 2024 | |
| MEDP Medpace Holdings | Maintains: Hold | $415 → $397 | $337.28 | +17.71% | 2 | Oct 14, 2024 | |
| ACCD Accolade | Maintains: Buy | $9 → $7.5 | $3.48 | +115.52% | 15 | Oct 9, 2024 | |
| EVH Evolent Health | Maintains: Buy | $33 | $11.41 | +189.22% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $59 | $33.70 | +75.07% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $10 | $9.44 | +5.93% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $13 → $23 | $26.20 | -12.21% | 7 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $11.14 | +25.67% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $1.97 | +229.95% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7.5 → $8 | $4.44 | +80.18% | 11 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $100 | $7.87 | +1,170.65% | 5 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $8.32 | +56.25% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $43 | $12.52 | +243.45% | 6 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $4.18 | +474.16% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $3.03 | +32.01% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $118.28 | -50.96% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $12.78 | +252.11% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $579.74 | -42.56% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $3.23 | +178.64% | 2 | May 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $21.76 | - | 3 | Jan 15, 2021 |
ICON Public Limited Company
Dec 18, 2024
Reiterates: Buy
Price Target: $295 → $284
Current: $207.51
Upside: +36.86%
IQVIA Holdings
Dec 12, 2024
Maintains: Buy
Price Target: $265 → $261
Current: $197.27
Upside: +32.31%
Phreesia
Dec 11, 2024
Maintains: Buy
Price Target: $31 → $34
Current: $25.16
Upside: +35.14%
Veeva Systems
Dec 6, 2024
Reiterates: Hold
Price Target: $207 → $261
Current: $224.15
Upside: +16.44%
Doximity
Nov 14, 2024
Maintains: Hold
Price Target: $35 → $49
Current: $57.83
Upside: -15.27%
Progyny
Nov 13, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $14.34
Upside: +32.50%
Privia Health Group
Nov 8, 2024
Maintains: Buy
Price Target: $24 → $27
Current: $20.07
Upside: +34.53%
Medpace Holdings
Oct 14, 2024
Maintains: Hold
Price Target: $415 → $397
Current: $337.28
Upside: +17.71%
Accolade
Oct 9, 2024
Maintains: Buy
Price Target: $9 → $7.5
Current: $3.48
Upside: +115.52%
Evolent Health
Aug 27, 2024
Maintains: Buy
Price Target: $33
Current: $11.41
Upside: +189.22%
Aug 9, 2024
Maintains: Buy
Price Target: $50 → $59
Current: $33.70
Upside: +75.07%
Aug 2, 2024
Maintains: Hold
Price Target: $15 → $10
Current: $9.44
Upside: +5.93%
Jul 18, 2024
Maintains: Hold
Price Target: $13 → $23
Current: $26.20
Upside: -12.21%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $11.14
Upside: +25.67%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $1.97
Upside: +229.95%
Mar 1, 2024
Maintains: Hold
Price Target: $7.5 → $8
Current: $4.44
Upside: +80.18%
Sep 7, 2022
Initiates: Hold
Price Target: $100
Current: $7.87
Upside: +1,170.65%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $8.32
Upside: +56.25%
Feb 28, 2022
Maintains: Neutral
Price Target: $42 → $43
Current: $12.52
Upside: +243.45%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $4.18
Upside: +474.16%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $3.03
Upside: +32.01%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $118.28
Upside: -50.96%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $12.78
Upside: +252.11%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $579.74
Upside: -42.56%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $3.23
Upside: +178.64%
Jan 15, 2021
Downgrades: Underperform
Price Target: n/a
Current: $21.76
Upside: -